Format

Send to

Choose Destination
Br J Dermatol. 2010 Oct;163(4):781-8. doi: 10.1111/j.1365-2133.2010.09915.x. Epub 2010 Sep 2.

Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?

Author information

1
Department of Dermatology, Bispebjerg Hospital, Bispebjerg bakke 23, Copenhagen 2400, Denmark.

Abstract

BACKGROUND:

The oncogenic potential of deregulated Notch signalling has been described in several haematopoietic malignancies. We have previously reported an increased expression of Notch1 in primary cutaneous CD30+ lymphoproliferative disorders, lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (pcALCL).

OBJECTIVES:

To investigate the functional importance of Notch signalling in cell lines derived from pcALCL.

METHODS:

Cell lines derived from pcALCL (Mac1, Mac2a and JK) were treated with different γ-secretase inhibitors (GSIs) (GSI I, IX, XX and XXI). The effects of GSIs on cell viability, apoptosis and cell cycle progression were measured as well as the impact of GSI I on the known prosurvival pathway Akt-mTOR-FOXO3a.

RESULTS:

Notch family members were expressed in all investigated pcALCL cell lines. GSI I had a marked proapoptotic effect, but GSI IX, XX and XXI were much less potent. The GSI I-triggered apoptosis was preceded by an accumulation of cells in the G2/M, cyclin B1-controlled phase of the cell cycle accompanied by an increase in the cyclin-dependent kinase inhibitor, p21(WAF/Cip) . GSI I induced the nuclear translocation of proapoptotic FOXO3a, probably via an Akt-independent pathway.

CONCLUSIONS:

Notch signalling may be a future therapeutic target for the treatment of advanced pcALCL.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center